Response of 33 UK patients with infantile‐onset Pompe disease to enzyme replacement therapy

Abstract

The outcome of treated patients remains heterogeneous despite attempts at immunomodulation. Failure to thrive at baseline and left ventricular dilation appear to be associated with poorer outcomes.